Drugs / GTU-MultiHIV B
GTU-MultiHIV B
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT02038842 | Mar 2014 → Oct 2015 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT01492985 | Jul 2013 → Oct 2016 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GTU-multiHIV B | “In this placebo-controlled phase II randomized clinical trial, 103 human immunodeficiency virus type 1 (HIV-1)-infected patients under cART (combined antiretroviral treatment)...” PMID 33568510 ↗ Apr 2021 |
| Known as | FIT Biotech GTU-MultiHIV B vaccine candidate | “FIT Biotech GTU-MultiHIV B vaccine candidate” NCT02038842 ↗ |
| Known as | GTU-multHIV B | “GTU-multHIV B vaccine and LIPO-5 vaccine” NCT01492985 ↗ |
| Modality | Vaccine | “a recombinant DNA vaccine (GTU-MultiHIV B clade)” PMID 33568510 ↗ Apr 2021 |
| Route | Intramuscular | “the GTU-MultiHIV B DNA vaccine or placebo administered by IM injections via Biojector” NCT01492985 ↗ |